Literature DB >> 7553630

Increased telomerase activity in mouse skin premalignant progression.

A Bednarek1, I Budunova, T J Slaga, C M Aldaz.   

Abstract

It has been postulated that the expression of the ribonucleoprotein telomerase is necessary to overcome cellular senescence and that malignant tumors must express telomerase to maintain their immortality. In most human adult tissues, telomerase activity is not detected. In contrast, several murine tissues express various levels of telomerase. Mouse skin however, does not show telomerase activity. Using the mouse skin chemical carcinogenesis system, a well-characterized model for studying premalignant and malignant progression, we assayed telomerase activity at various stages of premalignant papilloma progression by means of the recently developed telomeric repeat amplification protocol. We observed that at 10 weeks of promotion, only one mouse skin papilloma of 11 analyzed showed high levels of telomerase activity. The number of papillomas showing higher levels of telomerase activity increased at 20 weeks, and at 30 weeks of promotion, 100% of papillomas expressed significantly higher levels of telomerase. We learned from previous studies that early papillomas are diploid, well-differentiated lesions, whereas late papillomas are aneuploid and very dysplastic. It appears that the progressive increase in telomerase activity is associated with the increased level of genomic instability and the phenotypic progression of these premalignant tumors. It is also possible, however, that the increase in telomerase activity could be in part a consequence of an increase in the proportion of proliferating cells. Nevertheless, the mouse skin system may be a very useful in vivo model for the study and development of anti-telomerase therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553630

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Telomerase activity in plant extracts.

Authors:  K Heller; A Kilian; M A Piatyszek; A Kleinhofs
Journal:  Mol Gen Genet       Date:  1996-09-13

Review 2.  Telomerase activity, cell proliferation, and cancer.

Authors:  C W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

3.  PCB153 reduces telomerase activity and telomere length in immortalized human skin keratinocytes (HaCaT) but not in human foreskin keratinocytes (NFK).

Authors:  P K Senthilkumar; L W Robertson; G Ludewig
Journal:  Toxicol Appl Pharmacol       Date:  2011-12-22       Impact factor: 4.219

4.  Telomere dysfunction promotes metastasis in a TERC null mouse model of head and neck cancer.

Authors:  Bojana Bojovic; David L Crowe
Journal:  Mol Cancer Res       Date:  2011-05-18       Impact factor: 5.852

5.  Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.

Authors:  Atsuo Yoshino; Yoichi Katayama; Takao Fukushima; Takao Watanabe; Chiaki Komine; Takakazu Yokoyama; Kaoru Kusama; Itaru Moro
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

Review 6.  Reactivation of telomerase in cancer.

Authors:  Semih Can Akincilar; Bilal Unal; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2016-02-04       Impact factor: 9.261

Review 7.  Lessons from mice without telomerase.

Authors:  P M Lansdorp
Journal:  J Cell Biol       Date:  1997-10-20       Impact factor: 10.539

8.  Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy.

Authors:  A M Burger; M C Bibby; J A Double
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 9.  Current Insights to Regulation and Role of Telomerase in Human Diseases.

Authors:  Mert Burak Ozturk; Yinghui Li; Vinay Tergaonkar
Journal:  Antioxidants (Basel)       Date:  2017-02-28

10.  hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor.

Authors:  Ning Liu; Deqiang Ding; Wanyu Hao; Fan Yang; Xiaoying Wu; Miao Wang; Xiaoling Xu; Zhenyu Ju; Jun-Ping Liu; Zhangfa Song; Jerry W Shay; Yunliang Guo; Yu-Sheng Cong
Journal:  Nucleic Acids Res       Date:  2016-06-20       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.